分子对接和动力学模拟确定了海洋海绵衍生的Halinaquinone作为一种有希望的STAT4调节器,用于风湿性心脏病
S Skariyachan1, G K Mathamangalath2, D Sebastian3
1Department of Microbiology, St. Pius X College, Rajapuram, India.
SAR and QSAR in environmental research
|March 2, 2026
概括
海洋海绵化合物Halenaquinone显示出治疗风湿性心脏病 (RHD) 的潜力. 计算研究表明,它强烈抑制STAT4,这是RHD的关键目标,提供治疗可能性.
科学领域:
- 海洋天然产品化学 海洋天然产品化学
- 计算机化药物发现.
- 风湿性心脏病的研究研究.
背景情况:
- 风湿性心脏病 (RHD) 涉及复杂的分子途径.
- 信号传感器和转录4激活器 (STAT4) 参与了RHD的发病.
- 确定RHD的新型治疗点和药物是至关重要的.
研究的目的:
- 研究海洋海绵代谢物作为STAT4.4的潜在抑制剂.
- 为了评估海绵衍生分子哈莱纳,其与STAT4.4的相互作用.
- 在RHD的背景下探索Halenaquinone的治疗潜力.
主要方法:
- 在100种海绵代谢物对STAT4.4进行in silico选.
- 分子对接以评估结合亲和力和相互作用.
- 模拟分子动力学以分析复杂的稳定性和动力学.
- 免费能量分解和高级分析 (PCA,DCCM,FEL) 提供机械洞察力.
主要成果:
- 哈莱纳金被确定为一种强大的STAT4抑制剂,具有强大的结合亲和力 (-10.2 kcal/mol).
- 与参考药物普雷迪尼索隆相比,哈莱纳金显示出更强的结合作用.
- 分子动力学模拟证实了STAT4-Halenaquinone复合物的稳定性.
- 结合涉及结合和疏水相互作用,范德瓦尔斯和静电力作为关键贡献者.
结论:
- 对于RHD干预来说,STAT4是一个可行的计算目标.
- 哈莱纳金作为RHD的治疗剂具有显著的潜力.
- 这项研究强调了海洋海绵衍生化合物作为新型RHD治疗的有希望的来源.
相关概念视频
Rheumatic Heart Disease III: Medical Management
423
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
423
Rheumatic Heart Disease I: Introduction
656
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
656
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
793
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
793
The JAK-STAT Signaling Pathway
13.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.4K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.6K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
